Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Novozymes says Indian tariffs hits sales in its Monsanto alliance in Q1 -CFO

Published 2018-04-25, 03:56 a/m
© Reuters.  Novozymes says Indian tariffs hits sales in its Monsanto alliance in Q1 -CFO
NSISb
-
MON
-

COPENHAGEN, April 25 (Reuters) - Danish enzymes maker Novozymes' NZYMb.CO posted first-quarter earning slightly above forecasts, but sales through its BioAg alliance with U.S. seeds company Monsanto (NYSE:MON) Co MON.N were hit by Indian tariffs, its new CFO said on Wednesday.

* Firm posted operating profit (EBIT) of 1.016 billion Danish crowns ($166.43 million), in line with the same quarter last year, but slightly above the 990 million crowns expected by analysts polled by Reuters Within Novozymes' Agriculture & Feed segment, sales declined by 5 percent organically and 11 percent in Danish crowns compared with the first quarter of 2017

* Higher Indian import tariffs on peas and other pulses had had a bigger impact on BioAg sales than expected, Novozymes new chief financial officer Prisca Havranek-Kosicek said

* "Canada is a big exporter to India for these products, and the Indian government last year has put in tariffs that has then basically reduced the acreage that is planted in Canada for those crops," she told Reuters

* "We are in that business, that means we have an impact," she said

* She said the trade conflict between the United States and China added to the uncertainty for that business area going forward without wanting to specify further

* Shares in Novozymes fell 4.2 percent after the earnings report, lagging the overall Danish market

* Weak sales in the BioAg alliance was disappointing, Jyske Bank said in a note to clients ($1 = 6.1045 Danish crowns)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.